‘Disappointing’ results question the utility of liquid biopsy-guided cancer treatment

Circulating tumor DNA did not successfully predict whether patients with resected stage II colon cancer would benefit from adjuvant chemotherapy, according to findings presented at ASCO Gastrointestinal Cancers Symposium.
Results prompted researchers to stop the prospective phase 2/phase 3 clinical trial looking at the efficacy of using circulating tumor DNA (ctDNA) to determine if this patient population should get secondary treatment.
“The real-world applications of liquid biopsy for patients with gastrointestinal cancers continue to evolve rapidly,” Van K. Morris, MD, associate

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.